These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20981545)

  • 1. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
    Ocean AJ; Christos P; Sparano JA; Matulich D; Kaubish A; Siegel A; Sung M; Ward MM; Hamel N; Espinoza-Delgado I; Yen Y; Lane ME
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):379-88. PubMed ID: 20981545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
    Yen Y; Margolin K; Doroshow J; Fishman M; Johnson B; Clairmont C; Sullivan D; Sznol M
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):331-42. PubMed ID: 15148626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
    Mackenzie MJ; Saltman D; Hirte H; Low J; Johnson C; Pond G; Moore MJ
    Invest New Drugs; 2007 Dec; 25(6):553-8. PubMed ID: 17585372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
    Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
    Attia S; Kolesar J; Mahoney MR; Pitot HC; Laheru D; Heun J; Huang W; Eickhoff J; Erlichman C; Holen KD
    Invest New Drugs; 2008 Aug; 26(4):369-79. PubMed ID: 18278438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
    Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
    Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
    Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
    Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
    Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
    Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
    Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
    Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
    André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
    Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
    Lee J; Kim TY; Lee MA; Ahn MJ; Kim HK; Lim HY; Lee NS; Park BJ; Kim JS;
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):47-52. PubMed ID: 17364190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
    Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
    Ng EW; Sandler AB; Robinson L; Einhorn LH
    Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Alberts SR; Al-Khatib H; Mahoney MR; Burgart L; Cera PJ; Flynn PJ; Finch TR; Levitt R; Windschitl HE; Knost JA; Tschetter LK
    Cancer; 2005 Jan; 103(1):111-8. PubMed ID: 15558814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.